BridgeBio Pharma, Inc. (BBIO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about BridgeBio Pharma, Inc. (BBIO)
Company Performance

Current Price

as of Oct 11, 2024

$25.90

P/E Ratio

N/A

Market Cap

$4.69B

Description

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Metrics

Overview

  • HQPalo Alto, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBBIO
  • Price$25.9+3.77%

Trading Information

  • Market Cap$4.69B
  • Float78.13%
  • Average Daily Volume (1m)2,191,850
  • Average Daily Volume (3m)1,920,052
  • EPS-$2.64

Company

  • Revenue$219.12M
  • Rev Growth (1yr)32.11%
  • Net Income-$73.46M
  • Gross Margin13.65%
  • EBITDA Margin-7,890.87%
  • EBITDA-$171.07M
  • EV$5.90B
  • EV/Revenue26.95
  • P/EN/A
  • P/S21.37
  • P/BN/A
Documents
SEC Filings
8-K (2024-09-11)
8-K (2024-08-21)
8-K (2024-08-01)
8-K (2024-07-23)
8-K (2024-06-24)
8-K (2024-06-06)
8-K (2024-05-02)
8-K (2024-03-06)
8-K (2024-03-04)
8-K (2024-02-22)
8-K (2024-01-18)
8-K (2024-01-08)
8-K (2023-11-02)
8-K (2023-09-25)
8-K (2023-08-03)
8-K (2023-07-17)
8-K (2023-06-22)
8-K (2023-05-04)
8-K (2023-03-09)
8-K (2023-03-06)
8-K (2023-02-23)
10-Q (2024-08-01)
10-Q (2024-05-02)
10-Q (2023-11-02)
10-Q (2023-08-03)
10-Q (2023-05-04)
10-K (2024-02-22)
10-K (2023-02-23)
Factset Street Account
Cantor Fitzgerald initiates BBIO, CABA, FDMT, others (2023-10-23T21:23:52Z)
BridgeBio Pharma to present additional data from the Phase 3 ATTRibute-CM study in patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the AHA Scientific Sessions 2023 ($29.39, 0.00) (2023-11-09T12:35:21Z)
BridgeBio Pharma shares long-term data from ongoing Phase 2 study in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) at the Annual Congress of World Muscle Society (WMS) ($25.26, 0.00) (2023-10-09T11:32:21Z)
BridgeBio Pharma reports Q3 EPS ($1.08) vs FactSet ($0.79) [11 est, ($1.00)-(0.58)] ($26.65, 0.00) (2023-11-02T11:39:56Z)
BridgeBio Pharma presents additional clinical outcomes data from the Phase 3 ATTRibute-CM study of Acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) ($27.10, 0.00) (2023-11-12T15:45:14Z)
BridgeBio Pharma initiated buy at Citi ($27.88, 0.00) (2023-11-07T12:40:50Z)
BridgeBio and Resilience announce strategic multi-year partnership to advance BBP-631, BBP-812 and future gene therapy treatments ($25.41, 0.00) (2023-10-03T11:39:47Z)
Factset
Factset Business Description